Cancer Genomes Let Drugmakers Get Personal
Posted: July 30, 2012 at 10:13 am
One startup, H3 Biomedicines, uses genome data to design drugs aimed at small groups of patients.
Scott Balmer
A growing effort to personalize cancer medicine tries to link existing drugs to patients based on the specific genetic and molecular anomalies of a patient's cancer (see "Foundation Medicine: Personalizing Cancer Drugs"). But H3 Biomedicines, a startup in Cambridge, Massachusetts, wants to personalize cancer drugs from the beginning by designing drugs to target specific patient populations.
The company is taking advantage of cancer genome datathe DNA sequences of tumors from thousands of patientsmade available by the National Institutes of Health as The Cancer Genome Atlas (TCGA), and by the International Cancer Genome Consortium. When the company analyzed the first 3,000 cancer genomes in the TCGA web portal, it looked for cancer mutations that were shared by at least 1 percent of different cancer types. "Everything that occurs in greater than 10 percent was a known oncogene or known tumor suppressor [the two main classes of cancer-associated genes]," says Markus Warmuth, CEO of the company. But that was not the case for the less common mutations. For mutations shared between 1 and 10 percent of cancers, especially those shared by 5 percent or less of cancers, "most everything was novel," says Warmuth.
The lesson may be that cancer drugs will not play into the pharmaceutical industry's previous search for blockbuster drugs. "There's not some big novel cancer gene that no one had known before, one that induces 50 percent of breast cancer and 65 percent of lung cancer. That's not what the data tells us," says Warmuth.
So the company plans to develop drugs based on promising targets that may benefit only a small percentage of patients with a given cancer type. But another emerging theme in cancer discovery may increase the number of potential patients for any of H3's potential drugs: tumors in very different parts of the body can share some of the same genetic and molecular abnormalities. H3's lead target mutation can be found in some skin, breast, and blood cell cancers, with frequencies ranging from 3 percent to 10 percent for each.
They may need that time to address another challengehow to find the right patients to test its drugs. Many drug development trials in the past are thought to have failed because too many patients in the trial could not respond to the treatment. "Those patients would never respond to the drug because they don't actually have the genes that would respond," says Kevin Dalby, a medicinal chemist at the University of Texas at Austin. "So by knowing what you are looking for, you can choose your population much more astutely, so you would have a much better chance of having a successful clinical trial."
Warmuth thinks that the dropping cost of DNA sequencing will provide an opportunity to solve the patient problem. Rather than enrolling patients in a clinical trial and then determining whether they carry the particular mutation targeted by a candidate drug, patients could have their tumor's genome sequenced and then share the information in a database available to pharmaceutical companies. "Then you could more proactively approach patients in the future, and ask them if they are willing to become part of a clinical trial as drugs are being developed for particular genetic [changes]."
Link:
Cancer Genomes Let Drugmakers Get Personal
- BIS Research Study Highlights the Global Cell and Gene Therapy Drug Delivery Devices Market to Reach $10.82 Billion by 2030 investigated in the latest... - March 24th, 2021
- BioCentriq partners with Kytopen to advance production and manufacturing of cell and gene therapies - NJBIZ - March 24th, 2021
- Maze Therapeutics Reveals Its Initial Three Lead Programs Targeting Underlying Genetic Drivers of Life-Threatening Diseases - Business Wire - March 24th, 2021
- Krystal Biotech Announces Launch of Jeune, a Gene-Based Aesthetics Company, and Initial Phase 1 Safety Data for KB301 in Aesthetic Indications -... - March 24th, 2021
- Life Edit Therapeutics Announces Award from Cystic Fibrosis Foundation - BioSpace - March 24th, 2021
- Sarepta Therapeutics' Investigational Gene Therapy SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E Shows Sustained Expression and... - March 24th, 2021
- Sensorion Reports Full-Year 2020 Financial Results and Provides Business Highlights - Business Wire - March 24th, 2021
- Diabetic Dogs Needed for Study that Could Reduce or Eliminate Insulin Injections - PRNewswire - March 24th, 2021
- Actinium Announces Initiation of Patient Enrollment in Iomab-ACT Trial for Targeted Conditioning Prior to CD19 CAR T-Cell Therapy - PRNewswire - March 24th, 2021
- ElevateBio Announces Chief Scientific Officer of Regenerative Medicine, Melissa Carpenter, PhD, Elected to the International Society for Stem Cell... - March 24th, 2021
- With new results, Sarepta's 2nd gene therapy holds steady - BioPharma Dive - March 24th, 2021
- Orgenesis Enters into Collaboration Agreement with MIDA to Deploy OMPULs for Point-of-Care Research and Development of Promising Cell and Gene... - March 24th, 2021
- SparingVision Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting - GlobeNewswire - March 24th, 2021
- FTD Trials: The Now and the Future | ALZFORUM - Alzforum - March 24th, 2021
- Capsid titer quantification for AAV-based therapeutics - SelectScience - March 24th, 2021
- At 11.5% CAGR, Genetic Testing Market Size Expected to Reach 23143.42 Mn by 2027 Says Brandessence Market Research - PRNewswire - March 24th, 2021
- Hemophilia Gene Therapy Market is Thriving by World during Upcoming Year | Top Companies: Spark Therapeutics, Ultragenyx, Sangamo Therapeutics,... - March 24th, 2021
- Science Drives Surging Interest in Psychedelic Therapeutics - PRNewswire - March 24th, 2021
- First-in-Human Clinical Trial to Assess Gene Therapy for Alzheimer's Disease - UC San Diego Health - February 19th, 2021
- Selecta Biosciences and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR in Gene Therapy - PRNewswire - February 19th, 2021
- UC San Diego: First-in-Human Clinical Trial to Assess Gene Therapy for Alzheimers Disease - India Education Diary - February 19th, 2021
- Charles River acquires Cognate BioServices to expand cell and gene therapy programs - BioPharma-Reporter.com - February 19th, 2021
- Duchenne UK and Parent Project Muscular Dystrophy Award $350,000 to Address Immunological Challenges of Gene Therapy in Duchenne Muscular Dystrophy -... - February 19th, 2021
- Global Gene Therapy Market Outlook to 2030 - by Therapeutic Approach, Type of Gene Therapy, Type of Vectors Used, Therapeutic Areas, Route of... - February 19th, 2021
- Sensorion and Institut Pasteur announce new gene therapy collaboration - BioPharma-Reporter.com - February 19th, 2021
- Charles River Laboratories to Acquire Cognate BioServices to Create a Premier Scientific Partner for Cell and Gene Therapy Development - Business Wire - February 19th, 2021
- Affinia Therapeutics Announces Addition of Gene Therapy Scientific and Medical Experts to Leadership Team to Advance Novel Gene Therapy Platform and... - February 19th, 2021
- Charles River Dives Deep Into Cell and Gene Therapy With Cognate BioServices Acquisition - BioSpace - February 19th, 2021
- Most Elevated Read 2020 on Cancer Gene Therapy Market To Witness Robust Expansion Throughout The Forecast Period 2026 KSU | The Sentinel Newspaper -... - February 19th, 2021
- Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease -... - February 19th, 2021
- Global Genome Editing Market Is Expected to Reach USD 17.36 Billion by 2028 : Fior Markets - GlobeNewswire - February 19th, 2021
- REGENXBIO Announces Additional Positive Interim Phase I/IIa and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD - BioSpace - February 19th, 2021
- IO Therapy Combinations Spurring Growth of the Global Immuno-oncology Market, 2020 Report - Upcoming Product Launches in Adoptive Cell Therapy Segment... - February 19th, 2021
- The Europe cell and gene therapy market by revenue is expected to grow at a CAGR of over 23% during the period 20212026 - GlobeNewswire - February 17th, 2021
- Global Gene Therapy Market Industry Trends and Forecasts 2020-2030: Big Pharma Players and Analysis of Gene Therapy Related Initiatives -... - February 17th, 2021
- Global Gene Therapy Products Market Study including Growth Factors, New Top Players, Competitive Analysis by regions from 2021 to 2027 - The Courier - February 17th, 2021
- REGENXBIO Announces Additional Positive Interim Phase I/IIa and Long-Term Follow-Up Data of RGX-314 for the Treatment of Wet AMD - The Baytown Sun - February 17th, 2021
- Forge Biologics Receives FDA Fast Track, Orphan Drug, and Rare Pediatric Disease Designations for FBX-101 Gene Therapy for Patients with Krabbe... - February 17th, 2021
- Europe Cell and Gene Therapy Market Industry Outlook and Forecast Report 2021-2026 with Data-driven Insights on the Impact of COVID-19 -... - February 17th, 2021
- Dyno Therapeutics Announces Publication in Nature Biotechnology Demonstrating Use of Artificial Intelligence to Generate Unprecedented Diversity of... - February 17th, 2021
- Global Cancer Gene Therapy Market Insights, Size Estimation, Research Insights, COVID-19 Impact and Future Trends By 2028 KSU | The Sentinel... - February 17th, 2021
- Rentschler Biopharma to build new cell and gene therapy capabilities in the UK - BioSpace - February 17th, 2021
- Aldevron expands manufacturing capabilities in Madison - University of Wisconsin-Madison - February 17th, 2021
- Rare Disease Gene Therapy Market: Increasing cases of genetic diseases to drive the market - PharmiWeb.com - February 17th, 2021
- Sensorion Announces Third Gene Therapy Collaboration With Institut Pasteur Targeting Important Pediatric and Adult Deafness Segments - BioSpace - February 17th, 2021
- ProQR Announces Expert Perspectives Call on Disease Education and Endpoints in Usher Syndrome - GlobeNewswire - February 17th, 2021
- News > Science > Visualisation of 'dancing DNA' - University of Leeds - February 17th, 2021
- New study suggests genetic testing could be appropriate for all motor neuron disease (MND) patients whether or not they have a family history of the... - February 17th, 2021
- Gyroscope Therapeutics Announces Positive Interim Data from Phase I/II FOCUS Trial of Investigational Gene Therapy GT005 - Business Wire - February 17th, 2021
- Hemophilia A Market Domain to Witness Growth at a CAGR of 10.2% over the Study Period 2018-30 in the 7MM, Estimates DelveInsight - PRNewswire - February 17th, 2021
- Global Cancer Gene Therapy Market Is Projected to Grow at an Exponential Rate over 2020 to 2028 | Market Top Players Analysis, Revenue, Application,... - February 17th, 2021
- North America Virus Filtration Market 2020-2026: Surging Need for Virus Removal and Clearance amid COVID-19 Pandemic - PRNewswire - February 17th, 2021
- Janssen R&D puts itself into a strong position in ophthalmology through research collaboration with Verana Health - pharmaceutical-technology.com - February 17th, 2021
- CAR-T Cell Therapy Receives FDA Approval to Treat Certain Types of Large B-Cell Lymphoma - Curetoday.com - February 7th, 2021
- Liso-cel Receives FDA Approval for the Treatment of R/R Large B-Cell Lymphoma - Cancer Network - February 7th, 2021
- Europe Cell and Gene Therapy Market Size to Reach Revenues of USD 2.9 Billion by 2026 - Arizton - PRNewswire - February 7th, 2021
- The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight - Yahoo Finance - February 7th, 2021
- Gene Therapy Market by Therapeutic Approach, Type of Gene Therapy, Type of Vectors Used, Therapeutic Areas, Route of Administration, and Key... - February 6th, 2021
- Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease - BioSpace - February 6th, 2021
- Sio Gene Therapies Announces First Patient Dosed in Clinical Trial of AXO-AAV-GM2 in Patients with Tay-Sachs and Sandhoff Disease (GM2 Gangliosidosis)... - February 6th, 2021
- Regenerative Medicine Market to be Valued at USD 6.49 Billion by 2027 | The Escalating Burden of Chronic Diseases and Genetic Aberrations will be the... - February 6th, 2021
- FDA Issues More Guidance on Gene and Cell Therapy Products - JD Supra - February 6th, 2021
- Sio Gene Therapies Announces Receipt of $11.6 Million from Closing of the Sale of Arvelle Therapeutics - BioSpace - February 6th, 2021
- Adverum Biotechnologies Announces Publication of Preclinical Long-Term Safety Data on ADVM-022 IVT Gene Therapy - BioSpace - February 6th, 2021
- Aruvant Announces the European Medicines Agency (EMA) Granted Priority Medicines (PRIME) Designation to ARU-1801 for the Treatment of Sickle Cell... - February 6th, 2021
- Albumedix enters into collaboration agreement with Cell and Gene Therapy Catapult - PharmiWeb.com - February 6th, 2021
- The gene therapy market is projected to be worth USD 14.6 billion in 2030, growing at a CAGR of 30%, over the next decade, claims Roots Analysis -... - February 6th, 2021
- Retinal Gene Therapy Market: Advent of High-end Technologies to Support Development of the Market - BioSpace - February 6th, 2021
- Angiocrine Bioscience Announces Oral Presentation of Intravenous AB-205 Data during the Annual Transplantation & Cellular Therapy Meetings of ASCT... - February 6th, 2021
- M6P Therapeutics Announces Formation of Distinguished, Experienced Scientific Advisory Board - BioSpace - February 6th, 2021
- University of Sheffield receives record donation to support disadvantaged students and pioneering medical research - University of Sheffield News - February 6th, 2021
- Sanofi Succeeding with Blue-Chip Asset, Dupixent, While Other Programs Fall Away - BioSpace - February 6th, 2021
- Craig Lockhart named chief of hematology and oncology at MUSC - The Cancer Letter - January 31st, 2021
- Are Gene Therapies the Medicine of the Future? - BioSpace - January 29th, 2021
- Researchers use patients' cells to test gene therapy for rare eye disease - National Institutes of Health - January 29th, 2021
- Gene Therapy Market to Reach US$ 20.9 Billion by 2027, Globally |CAGR: 29.7%|UnivDatos Market Insights - PR Newswire India - January 29th, 2021
- First hybrid gene therapy shows early promise in treating long QT syndrome - Newswise - January 29th, 2021
- Cell and Gene Therapy Firms Gear up to Revolutionize Manufacturing - Labiotech.eu - January 29th, 2021
- Cell and Gene Therapy Market Size to Reach USD 7,250.0 Million by 2028 | Increasing Investments in Production Capacity Expansion for Cell and Gene... - January 29th, 2021
- Provention Bio Announces Key Findings from Pre-clinical Proof-of-concept Study for PRV-3279 for the Prevention of Immunogenicity of Gene Therapy -... - January 29th, 2021